One-year infant outcome in women with early-onset hypertensive disorders of pregnancy

BJOG. 2008 Jan;115(2):290-8. doi: 10.1111/j.1471-0528.2007.01544.x. Epub 2007 Oct 25.

Abstract

Objectives: To evaluate the role of plasma volume expansion on 1-year infant outcome after severe hypertensive disorders of pregnancy and to determine prognostic factors for adverse neurodevelopmental infant outcome.

Design: Randomised controlled trial, observational prognostic study.

Setting: Two university hospitals in Amsterdam, The Netherlands.

Population: One hundred and seventy-two infants alive of 216 mothers with severe hypertensive disorders of pregnancy who were randomised for a temporising management strategy with or without plasma volume expansion.

Methods: At 1 year of corrected age, a neurological examination according to Bayley (mental development index [MDI] and psychomotor development index [PDI]) and Touwen was performed.

Main outcome measures: Adverse neurodevelopmental infant outcome was defined as a MDI/PDI score below 70 and/or an abnormal Touwen. Risk factors for adverse neurodevelopmental outcome were explored by univariate and multivariate analyses.

Results: Adverse neurodevelopmental infant outcome was observed in 31 infants (18%). There were no differences between the randomisation groups. In multivariate analysis, an association with abnormal umbilical artery/middle cerebral artery Doppler ratio higher than the median, major neonatal morbidity, higher education of the parents, multiparity and Caucasian ethnicity was observed.

Conclusion: Nearly 70% of the infants were alive at 1 year without adverse neurodevelopmental outcome. Maternal plasma volume expansion during pregnancy has no effect on 1-year infant outcome. The prediction of adverse outcome at 1 year by perinatal parameters is limited.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Female
  • Fetal Growth Retardation / etiology*
  • Gestational Age
  • Humans
  • Hypertension, Pregnancy-Induced / drug therapy*
  • Infant
  • Intellectual Disability / embryology*
  • Male
  • Plasma Substitutes / therapeutic use*
  • Pregnancy
  • Pregnancy Outcome
  • Prenatal Exposure Delayed Effects / etiology*
  • Psychomotor Disorders / embryology*

Substances

  • Plasma Substitutes